Lantheus (NASDAQ:LNTH) Issues Quarterly Earnings Results

Lantheus (NASDAQ:LNTH) announced its earnings results on Thursday. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.27, Briefing.com reports. The business had revenue of $384.01 million for the quarter, compared to analyst estimates of $363.42 million. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period last year, the firm posted $1.70 earnings per share. Lantheus updated its FY 2025 guidance to 5.500-5.650 EPS.

Lantheus Price Performance

LNTH stock traded down $2.62 during trading on Friday, reaching $51.07. 1,757,334 shares of the company were exchanged, compared to its average volume of 1,261,428. The stock’s 50 day moving average price is $54.09 and its 200 day moving average price is $68.72. Lantheus has a 52-week low of $47.25 and a 52-week high of $111.29. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The company has a market cap of $3.47 billion, a P/E ratio of 13.58 and a beta of 0.04.

Insider Activity at Lantheus

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,812,000 shares of company stock worth $382,427,380 in the last three months. Corporate insiders own 1.50% of the company’s stock.

Institutional Trading of Lantheus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. B. Riley Wealth Advisors Inc. acquired a new position in Lantheus in the 2nd quarter valued at about $251,000. State of Wyoming grew its holdings in shares of Lantheus by 36.7% during the second quarter. State of Wyoming now owns 2,806 shares of the medical equipment provider’s stock worth $230,000 after buying an additional 754 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Lantheus by 330.5% in the second quarter. Tower Research Capital LLC TRC now owns 12,114 shares of the medical equipment provider’s stock valued at $992,000 after buying an additional 9,300 shares during the last quarter. Vident Advisory LLC lifted its stake in shares of Lantheus by 46.7% during the second quarter. Vident Advisory LLC now owns 69,575 shares of the medical equipment provider’s stock valued at $5,695,000 after buying an additional 22,148 shares during the period. Finally, Two Sigma Securities LLC acquired a new stake in Lantheus during the second quarter worth approximately $407,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several recent research reports. Weiss Ratings downgraded shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. JMP Securities lowered their target price on Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 7th. William Blair reissued a “market perform” rating on shares of Lantheus in a report on Wednesday, July 16th. Truist Financial set a $63.00 price target on Lantheus and gave the stock a “hold” rating in a research note on Monday, August 11th. Finally, The Goldman Sachs Group set a $77.00 price target on Lantheus and gave the stock a “neutral” rating in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $74.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.